NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.
Failure of a vital catalyst in psoriasis leaves Immunic’s approach at risk of obsolescence.
The company’s attempt to segment Braf-mutant cancers further isn’t going smoothly.
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Fianlimab maintains its leading activity, but more Opdualag competition is not far behind.
Astrazeneca’s SGLT2 matches Lilly and Boehringer’s rival in heart failure with preserved ejection fraction, but the big battle could be uptake.